Notably, the National Comprehensive Cancer Network (NCCN) provides considerations for Pneumocystis jiroveci pneumonia (PJP) and other viral prophylaxis for patients being treated with Bruton tyrosine kinase (BTK) inhibitors [7]. This evidence concerns the gene BTK and pneumocystosis.